Valuation: LOTUS PHARM

Market Cap 97.36L 86.94L 80.32L 72.78L 1.36Cr 92Cr 1.38Cr 9.66Cr 3.83Cr 48Cr 3.65Cr 3.58Cr 152.66Cr P/E 2009
3.88x
P/E 2010 4.84x
Enterprise Value 1.44Cr 1.28Cr 1.19Cr 1.08Cr 2.01Cr 136.53Cr 2.04Cr 14Cr 5.65Cr 72Cr 5.4Cr 5.28Cr 225.53Cr EV / Sales 2009
1.02x
EV / Sales 2010 0.95x
Free-Float
99%
Yield 2009 *
-
Yield 2010 -
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-2.54%+1.31%+55.10%+120.84% 1,13500Cr
-1.42%+3.23%+37.07%+74.26% 64TCr
+0.16%+0.08%+25.14%+97.36% 50TCr
-0.31%+3.09%+43.92%+64.55% 38TCr
-1.34%-0.47%+66.63%+40.56% 36TCr
-0.68%+2.65%+22.46%+51.48% 29TCr
-1.20%+3.04%+2.62%+26.97% 27TCr
-1.79%+1.57%+49.97%+60.87% 24TCr
-0.73%-0.10%+29.24%+101.19% 19TCr
Average -0.67%+2.17%+36.91%+70.90% 44.49TCr
Weighted average by Cap. -0.26%+2.66%+40.99%+82.13%

Financials

2009 2010
Net sales 5.78Cr 5.16Cr 4.77Cr 4.32Cr 8.09Cr 548.92Cr 8.22Cr 57Cr 23Cr 287.6Cr 22Cr 21Cr 906.73Cr 7.27Cr 6.49Cr 6Cr 5.43Cr 10Cr 690.1Cr 10Cr 72Cr 29Cr 361.57Cr 27Cr 27Cr 1.14TCr
Net income 1.64Cr 1.47Cr 1.36Cr 1.23Cr 2.3Cr 155.99Cr 2.34Cr 16Cr 6.46Cr 82Cr 6.17Cr 6.04Cr 257.67Cr 1.44Cr 1.29Cr 1.19Cr 1.08Cr 2.02Cr 136.93Cr 2.05Cr 14Cr 5.67Cr 72Cr 5.41Cr 5.3Cr 226.19Cr
Net Debt 5.29 4.73 4.37 3.96 7.4 502.54 7.53 52.55 20.81 263.3 19.87 19.44 830.11 4.65 4.15 3.83 3.47 6.5 441.11 6.61 46.13 18.26 231.11 17.44 17.07 728.64
Logo LOTUS PHARM
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
-